Welcome to our dedicated page for Grail SEC filings (Ticker: GRAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GRAIL filings document the public-company disclosures of a healthcare issuer developing and commercializing Galleri, a multi-cancer early detection test built on a targeted methylation-based platform. Its 8-K reports furnish operating and financial results, corporate presentations, clinical and regulatory updates, and other material events related to the company’s cancer detection business.
Regulatory filings also cover proxy governance, shareholder voting matters, board and leadership succession disclosures, emerging growth company status, and capital-structure activity. Recent records include securities purchase agreements, common stock and pre-funded warrant disclosures, resale registration-related materials, an at-the-market equity distribution agreement, and lease obligations, alongside exhibits and risk-oriented disclosures tied to GRAIL’s operations and financing needs.
CHASE WILLIAM J reported acquisition or exercise transactions in this Form 4 filing.
GRAIL, Inc. director William J. Chase received a grant of 408 shares of common stock in the form of deferred stock units. The award was issued under the company’s deferred stock program and 2024 Incentive Award Plan in lieu of $20,342.47 of cash director fees.
The grant was valued at $49.79 per share, equal to the closing price of GRAIL’s common stock on April 15, 2026, and vests immediately on the grant date. After this compensation-related award, Chase directly holds 37,211 shares of GRAIL common stock.
GRAIL, Inc. director Gregory L. Summe received an equity-based compensation award rather than cash fees. He acquired 631 deferred stock units valued at $49.79 per share, in lieu of $31,438.36 of director fees, under the company’s deferred stock program and 2024 Incentive Award Plan. The units vest immediately on the grant date, and following this grant he holds 39,754 shares of common stock directly.
GRAIL, Inc.’s Chief Financial Officer, Aaron Freidin, reported an automatic sale of 45,806 shares of common stock at a weighted average price of $49.9176 per share. According to the footnote, these were broker-executed “sell-to-cover” transactions to pay withholding taxes upon award vesting and share delivery. After these sales, Freidin directly holds 260,669 shares of GRAIL common stock.
GRAIL, Inc. director and Chief Executive Officer Robert P. Ragusa reported an automatic tax-related share sale. On the transaction date, an executing broker sold 123,502 shares of Common Stock in a sell-to-cover transaction to satisfy withholding taxes tied to award vesting and share delivery.
The broker executed the sales as part of a block trade at a weighted average price of $49.9176 per share. After these transactions, Ragusa directly holds 518,582 shares of GRAIL common stock, indicating he retains a substantial equity position despite the tax-driven sale.
GRAIL, Inc. President and director Joshua J. Ofman reported an automatic sale of common stock tied to tax withholding. An executing broker sold 61,665 shares in a sell-to-cover transaction following award vesting at a weighted average price of $49.9176 per share. After these sales, Ofman directly holds 371,216 shares of GRAIL common stock. The footnote explains the shares were sold to cover withholding taxes and executed as part of a block trade across multiple transactions.
Aaron Freidin submitted a Form 144 notice proposing to sell 79,460 shares of Common Stock acquired upon vesting of restricted stock units on 04/03/2026.
The filing also lists recent sales by Mr. Freidin during the prior three months: 9,573 shares sold on 03/02/2026, 655 shares on 03/05/2026, and 2,492 shares on 03/09/2026, with the recorded proceeds shown for each transaction.
Grayscale Analytics, Inc. reported Rule 144 transactions involving Common Stock. The filing lists 106,970 shares of Common Stock acquired upon vesting of restricted stock units under the issuer's equity incentive plans on 04/03/2026. It also discloses three sales by a reporting holder: 17,002, 690, and 2,937 shares on 03/02/2026, 03/05/2026, and 03/09/2026, respectively, with the dollar amounts shown alongside each sale. Shares outstanding are listed as 41,134,219 as of 04/06/2026.
Grayscale Alpha Group (GRAL) insider transactions disclosed under Rule 144. Director Robert P. Ragusa reported open-market dispositions of Common Stock: 37,504 shares on 03/02/2026 for $1,881,417.06, 980 shares on 03/05/2026 for $51,949.80, and 7,461 shares on 03/09/2026 for $357,296.13. The filing also reports 214,240 shares acquired upon vesting of restricted stock units on 04/03/2026 as compensation for services rendered.
GRAIL Inc ownership disclosure: The Vanguard Group filed an amendment stating it beneficially owns 0 shares (0%) of GRAIL Inc common stock. The filing explains an internal realignment on January 12, 2026 that disaggregated certain Vanguard subsidiaries and business divisions for SEC reporting; those entities will report separately under Release No. 34-39538. The amendment is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection using its Galleri blood test, which looks for abnormal DNA methylation patterns to detect a cancer signal and predict the cancer signal of origin. Galleri can screen for over 50 cancer types, many without existing screening guidelines, and has been used in more than 475,000 commercial tests as of December 31, 2025.
The company highlights large interventional trials. PATHFINDER 2 showed a positive predictive value of 61.6%, a cancer signal origin accuracy of 92%, a 0.4% false positive rate, and a more than seven-fold increase in cancers found when added to recommended screenings. The randomized NHS-Galleri Trial did not meet its primary endpoint of reducing combined stage 3 and 4 cancers, but showed substantial reductions in stage 4 diagnoses (greater than 20% in the second and third screening rounds), more stage 1–2 cancers, and a four-fold increase in detection versus standard screening alone.
In January 2026 GRAIL submitted a premarket approval application to the FDA for Galleri using NHS-Galleri and PATHFINDER 2 data and a bridging analysis. A February 2026 law created a future Medicare coverage category for FDA-approved multi-cancer early detection tests, with potential national coverage beginning January 1, 2029 for ages 50–65. Key risks include a history of significant net losses, heavy dependence on Galleri for revenue, uncertainty around FDA approval, reimbursement and guideline inclusion, perpetual high single-digit royalties owed to Illumina, reliance on sole suppliers for core inputs, and substantial clinical, regulatory and implementation uncertainty despite strong trial signals.